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Adiponectin and its receptors, AdipoR1 and AdipoR2, regulate glucose and fatty acid metabolism partly via
activation of AMP-activated protein kinase (AMPK). Recent work in Nature Medicine (Holland et al., 2011)
suggests that adiponectin stimulates ceramidase activity through AdipoR1 and AdipoR2, an activity poten-
tially involved in promoting cell survival.Adiponectin is a major insulin-sensitizing
adipokine (Berg et al., 2001; Fruebis
et al., 2001; Yamauchi et al., 2001). Adipo-
nectin levels are decreased in cases of
obesity and type 2 diabetes, a finding
that has attracted enormous interest in
the scientific community. Adiponectin
stimulates AMP-activated protein kinase
(AMPK), and this action has been impli-
cated in its insulin-sensitizing function in
liver and muscle (Yamauchi et al., 2002;
Nawrocki et al., 2006). Both adiponectin
receptors, AdipoR1 andAdipoR2 (Yamau-
chi et al., 2003), mediate the major part of
the insulin-sensitizing action of adiponec-
tin in liver, while AdipoR1 primarily does
so inmuscle (Yamauchi et al., 2007; Iwabu
et al., 2010). Although it was previously
shown thatAdipoR1andAdipoR2 regulate
glucose and fatty acid metabolism partly
via activation of AMPK, Ca2+, and PPARa
signaling pathways, it was not known
whether these signaling pathways are
sufficient to explain the pleiotropic actions
of adiponectin. This study adds ceramide
signaling as a new pathway involved in
mediating such pleiotropic effects.
Scherer and colleagues also confirm
that adiponectin ameliorates insulin resis-
tance induced by a high-fat diet (HFD)
in an AdipoR1- or AdipoR2-dependent
fashion (Holland et al., 2011). Interest-ingly, they demonstrate that adiponectin
lowers cellular ceramide levels via acti-
vation of ceramidase, which converts
ceramide to sphingosine, an effect that
appears to be dependent on activation
of AdipoR1 or AdipoR2. They found that
in liver, overexpression of adiponectin,
AdipoR1, or AdipoR2 reduces hepatic
ceramide levels and improves insulin
sensitivity, while deficiency of adiponectin
increases hepatic ceramide levels and
exacerbates insulin resistance. Because
increased ceramide levels correlate with
impaired insulin action in muscle (Savage
et al., 2007), it is tempting to speculate
that the relationship between adiponec-
tin-induced changes in ceramide levels
and those in insulin sensitivity may be
causal; this hypothesis should be exam-
ined experimentally.
Accumulation of ceramide has also
been implicated in both b cell decompen-
sation and heart failure induced by a HFD.
This may be due to reduced ceramidase
activity associated with reduced sphingo-
sine, leading to reduced sphingosine
1-phosphate (S1P), a potent inhibitor of
apoptosis generated via phosphorylation
of sphingosine by sphingosine kinase.
Scherer and colleagues use their elegant
model of conditionally induced apoptosis
to demonstrate that adiponectin both in-creases S1P and protects from apoptotic
cell death induced by either palmitate or
C2-ceramide in cardiac myocytes and
pancreatic b cells (Holland et al., 2011).
Because this protection is reversed by
either an inhibitor of ceramide biosyn-
thesis or S1P itself, it seems likely that adi-
ponectin-induced S1P generation pro-
tects cardiac myocytes and b cells from
cell death.
In this study, adiponectin significantly
reducedhepaticceramide levelsandblood
glucose levels inmice deficient in LKB1, an
upstream activator of AMPK, which had
increased basal hepatic ceramide levels
and blood glucose levels compared to
controls (Holland et al., 2011). From these
data, they argue that adiponectin reduces
hepatic ceramide levels independent of
AMPK. No evidence yet exists to support
this claim, as it may be difficult to draw
a conclusion on the role of AMPK per se
in decreasing glucose levels or on the role
of adiponectin on lowering ceramide in
this system. Moreover, the activation of
AMPK and Ca2+ signaling pathways
occurs within minutes after adiponectin
stimulation, whereas activation of cerami-
dase appears to occur within a half hour,
raising some question of whether cerami-
dase is the most upstream event following
AdipoR1 or AdipoR2 activation., February 2, 2011 ª2011 Elsevier Inc. 123
A B
Figure 1. Adiponectin-Mediated Intracellular Signaling Pathways via AdipoR1 and AdipoR2
(A and B) Glucose and lipid metabolism regulated by adiponectin occurs within minutes, while antiapop-
totic effects regulated by adiponectin occur within a half hour. Solid lines indicate pathways with reported
cause-effect relationship, while hashed lines indicate those without. In skeletal muscle and liver,
adiponectin stimulates AMPK, extracellular Ca2+ influx, and PPARa, which are involved in glucose and
lipid metabolism in part via mitochondrial biogenesis (A). In this study, Holland et al. (2011) propose
that in cardiac myocytes, b cells, and liver, adiponectin reduces levels of ceramide and increases those
of S1P, which may be implicated in antiapoptosis (B). This may also be implicated in glucose and lipid
metabolism, although the latter is only a parallel effect at present.
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PreviewsAdipoR1 and AdipoR2 belong to the
progesterone and adiponectin Q receptor
(PAQR) family. Some PAQR family
members have been reported to contain
sequence homology with alkaline cerami-
dase, and transfection of the yeast PAQR
Izh2p enhances ceramidase activity in
the cell. Indeed, transfection of cDNAs
encoding AdipoR1 or AdipoR2 signifi-
cantly enhanced ceramidase activity,
and this activity was further enhanced by
adiponectin in HEK293 cells (Holland
et al., 2011).
While this study reveals an involvement
of ceramide pathway downstream of Adi-
poR1 and AdipoR2 in pleiotropic actions
of adiponectin, several points need to
be clarified in future investigations. First,
it is unclear whether and to what extent
alterations of hepatic ceramide levels
regulated by adiponectin-AdipoR1/Adi-
poR2 may be causally implicated in the
regulation of insulin sensitivity. Second,
as Scherer and colleagues acknowledge,
it remains largely unknown whether
adiponectin-AdipoR1/AdipoR2-activated124 Cell Metabolism 13, February 2, 2011 ª2ceramidase pathway is independent,
parallel, or even an upstream pathway of
AMPK or Ca2+ signaling. This point could
be addressed through a detailed time
course of these signals in response to
adiponectin. Inducible ablation of AMPK,
rather than ablation of LKB1, could also
determine the role of AMPK on adiponec-
tin-induced changes in ceramide levels in
liver as well as in muscle, another impor-
tant organ in the regulation of glucose
and fatty acid metabolism. Last, even
though AdipoR1 and AdipoR2 play roles
in the regulation of ceramidase activity, it
should next be determined whether the
ceramidase activity is intrinsic to the
receptor or whether ceramidase is indi-
rectly activated upon adiponectin stimu-
lation via an unknown mechanism.
This study shows that AdipoR1 and
AdipoR2 mediate not only metabolic
actions but also the antiapoptotic actions
of adiponectin. In order for adiponectin
to regulate these pleiotropic biological
actions, it appears to regulate more
diverse and complex pathways, such011 Elsevier Inc.as ceramide and S1P downstream of Adi-
poR1 and AdipoR2, in addition to those
originally identified, such as AMPK,
Ca2+, and PPARa (Yamauchi et al., 2003;
Iwabu et al., 2010). It will be important to
determine upstream, downstream, or
even circuit relationships of these
complex pathways as well as to correlate
each of the signals to the downstream
pleiotropic actions of adiponectin. This
work has added a new layer to the
working model for adiponectin-induced
signaling pathways via AdipoR1 and
AdipoR2 (Figure 1). This new knowledge
adds to our fundamental understanding
of this pleiotropic adipokine and to the
development of versatile treatment strate-
gies toward obesity-linked diseases such
as type 2 diabetes.REFERENCES
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